Francois Vigneault, Shape CEO

Ex­clu­sive: Roche tees up $3B+ for Shape's RNA edit­ing plat­form, with the bold promise of 'one-time' cures for Alzheimer's, Parkin­son's

Alzheimer’s and Parkin­son’s are two of the tough­est nuts to crack in bio­phar­ma. Many have tried to de­vel­op ef­fec­tive ther­a­pies and many have failed, lead­ing Big Phar­ma to re­cede from neu­ro­science in the late 2000s and ear­ly 2010s. Even for Bio­gen’s con­tro­ver­sial Aduhelm ap­proval, the first new Alzheimer’s drug in near­ly 20 years, sig­nif­i­cant ques­tions re­main re­gard­ing its ef­fec­tive­ness.

None of that is scar­ing Roche, how­ev­er, as the Swiss drug­mak­er is can­non­balling straight in­to the deep end with a new col­lab­o­ra­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.